Analyst firm reaffirmed rating on Ardelyx stock, while an insider sold company shares.

1 report, 1 independent Updated Jun 27

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Leerink partners Mike Kelliher

Keep exploring

Part of

Leerink partners maintained a Buy rating on Ardelyx on June 25, 2025. All 1 developments

The entities involved

Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38
Mike Kelliher
Nothing else this week.

Coverage

Newest first; wire copies grouped

Jun 27themarketsdaily.com